Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Unlocking Potential – Analyzing ABBV Stock for Investors

A strong performer from today's afternoon trading session is AbbVie, whose shares rose 3.8% to $196.25 per share. For those of you thinking about investing in the stock, here is a brief value analysis of the stock using the company's basic fundamental ratios.

AbbVie's Valuation Is in Line With Its Sector Averages:

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 22.94 and an average price to book (P/B) ratio of 3.19. In contrast, AbbVie has a trailing 12 month P/E ratio of 93.5 and a P/B ratio of 104.17.

AbbVie has moved -0.1% over the last year compared to 18.6% for the S&P 500 — a difference of -18.7%. AbbVie has a 52 week high of $218.66 and a 52 week low of $163.81.

Increasing Revenues but Narrowing Margins:

2019 2020 2021 2022 2023 2024
Revenue (M) $33,266 $45,804 $56,197 $58,054 $54,318 $56,334
Operating Margins 39% 25% 32% 31% 23% 16%
Net Margins 24% 10% 21% 20% 9% 8%
Net Income (M) $7,882 $4,616 $11,542 $11,836 $4,863 $4,278
Net Interest Expense (M) -$1,509 -$2,280 -$2,384 -$2,044 -$1,684 -$2,160
Depreciation & Amort. (M) $464 $666 $803 $778 $752 $764
Diluted Shares (M) 1,484 1,673 1,777 1,778 1,773 1,773
Earnings Per Share $5.28 $2.72 $6.45 $6.63 $2.72 $2.39
EPS Growth n/a -48.48% 137.13% 2.79% -58.97% -12.13%
Avg. Price $65.1 $80.3 $104.86 $142.88 $144.37 $196.12
P/E Ratio 12.28 29.41 16.18 21.49 52.88 81.72
Free Cash Flow (M) $12,772 $16,790 $21,990 $24,248 $22,062 $17,832
CAPEX (M) $552 $798 $787 $695 $777 $974
EV / EBITDA 9.13 16.32 13.46 16.24 22.36 41.87
Total Debt (M) $66,728 $86,022 $76,670 $63,270 $59,385 $73,645
Net Debt / EBITDA 1.99 6.45 3.57 2.86 3.45 6.88
Current Ratio 3.18 0.84 0.79 0.96 0.87 0.66

AbbVie has declining EPS growth, not enough current assets to cover current liabilities because its current ratio is 0.66, and a highly leveraged balance sheet. On the other hand, the company benefits from growing revenues and increasing reinvestment in the business and generally positive cash flows. Furthermore, AbbVie has decent operating margins with a negative growth trend.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS